Table 1 Baseline characteristics in patients undergoing CAG and/or PCI.

From: Predictive value of inflammatory prognostic index for contrast-induced nephropathy in patients undergoing coronary angiography and/or percutaneous coronary intervention

 

Inflammatory Prognostic Index Quartile

Variables

Quartile 1 (≤ 0.11)

Quartile 2 (0.12–0.74)

Quartile 3 (0.75–1.93)

Quartile 4 (≥ 1.94)

P-value

(n = 835)

(n = 835)

(n = 835)

(n = 835)

 

Demographic and clinical characteristics

 

Age, years, M (SD)

63.49 ± 10.31

64.54 ± 10.92

63.77 ± 10.38

64.04 ± 10.50

0.209

Female sex, n (%)

200 (24.0)

235 (28.1)

576 (30.4)

622 (27.9)

0.029

Current smoking, n (%)

278 (33.3)

276 (33.1)

248 (29.7)

253 (30.3)

0.222

Current drinking, n (%)

599 (7.1)

58 (6.9)

51 (6.1)

66 (7.9)

0.509

SBP, mm Hg, M (SD)

131.80 ± 19.06

129.84 ± 19.62

127.22 ± 20.09

125.55 ± 21.10

 < 0.001

DBP, mm Hg, M (SD)

79.28 ± 12.69

78.19 ± 12.42

78.08 ± 27.16

75.57 ± 13.54

 < 0.001

BMI, kg/m2, M (SD)

24.22 ± 3.37

24.34 ± 2.98

23.85 ± 3.10

23.52 ± 3.24

 < 0.001

LOS, days, M (SD)

7.88 ± 6.12

9.66 ± 7.09

12.29 ± 9.01

16.15 ± 10.97

 < 0.001

EF (%), M (SD)

62.68 ± 9.74

59.41 ± 11.87

59.55 ± 12.63

57.32 ± 13.11

 < 0.001

Prior MI, n (%)

105 (12.6)

58 (6.9)

27 (3.2)

19 (2.3)

 < 0.001

Prior CVA, n (%)

55 (6.6)

52 (6.2)

40 (4.8)

59 (7.1)

0.245

Prior PCI, n (%)

20 (2.4)

20 (2.4)

10 (1.2)

13 (1.6)

0.174

Prior CABG, n (%)

215 (25.8)

141 (16.9)

96 (11.5)

59 (7.1)

 < 0.001

Complication

 

Hypertension, n (%)

533 (63.8)

492 (58.9)

430 (51.5)

419 (50.2)

 < 0.001

DM, n (%)

320 (38.3)

276 (33.1)

231(27.7)

229 (27.4)

 < 0.001

Hyperlipemia, n (%)

291 (34.9)

285 (34.1)

189 (22.6)

143 (17.1)

 < 0.001

CKD, n (%)

53 (6.3)

65 (7.8)

86 (10.3)

139 (16.6)

 < 0.001

Hepatic insufficiency, n (%)

39 (4.7)

60 (7.2)

65 (7.8)

95 (11.4)

 < 0.001

ACS, n (%)

580 (69.5)

509 (61.0)

354 (42.4)

332 (39.8)

 < 0.001

Pulmonary infection, n (%)

115 (13.8)

235 (28.1)

420 (50.3)

546 (65.4)

 < 0.001

Valvular heart disease, n (%)

131 (15.7)

198 (23.7)

279 (33.4)

348 (41.7)

 < 0.001

AF, n (%)

81 (9.7)

130 (15.6)

146 (17.5)

196 (23.5)

 < 0.001

PAH, n (%)

26 (3.1)

64 (7.7)

130 (15.6)

149 (17.8)

 < 0.001

HF, n (%)

17 (2.0)

34 (4.1)

23 (2.8)

53 (6.3)

 < 0.001

Medications before procedures

     

Diuretics, n (%)

139 (16.6)

250 (29.9)

342 (41.0)

452 (54.1)

 < 0.001

CCB, n (%)

275 (32.9)

202 (24.2)

167 (20.0)

126 (15.1)

 < 0.001

ACEI/ARB/ARNI, n (%)

326 (39.0)

266 (31.9)

211 (25.3)

189 (22.6)

 < 0.001

β-blockers, n (%)

470 (56.3)

426 (51.0)

408 (48.9)

340 (40.7)

 < 0.001

Statins, n (%)

715 (85.6)

588 (70.4)

469 (56.2)

370 (44.3)

 < 0.001

DAPT, n (%)

725 (86.8)

589 (70.5)

444 (53.2)

353 (42.3)

 < 0.001

Procedural characteristics

     

PCI, n (%)

671 (80.4)

549(65.7)

411(49.2)

319(38.2)

 < 0.001

Number of infarcted arteries

2.70 ± 0.79

2.75 ± 0.76

2.65 ± 0.83

2.75 ± 0.82

 < 0.001

Stent number

1.51 ± 0.82

1.59 ± 0.86

1.62 ± 0.92

1.65 ± 0.95

0.094

Hydration therapy, n (%)

806 (96.5)

764 (91.5)

732 (87.7)

743 (89.0)

 < 0.001

Repeated angiography(7 days)

689 (82.5)

586 (70.2)

463 (55.4)

367 (44.0)

 < 0.001

Contrast volume, ml, M (SD)

347.97 ± 143.76

305.69 ± 165.52

301.45 ± 153.54

254.60 ± 174.38

 < 0.001

Baseline chemistry

     

ALP, g/L, M (SD)

40.99 ± 3.59

39.91 ± 3.74

39.35 ± 4.31

36.86 ± 5.38

 < 0.001

UREA, mmol/L, M (SD)

5.74 ± 2.21

6.11 ± 3.19

6.39 ± 3.41

7.25 ± 4.54

 < 0.001

Scr, μmol/L, M (SD)

80.29 ± 29.72

86.78 ± 48.50

91.83 ± 70.86

106.11 ± 104.56

 < 0.001

Hemoglobin, g/L, M (SD)

137.01 ± 17.07

133.50 ± 17.66

132.33 ± 18.49

125.53 ± 22.98

 < 0.001

NE, 10^9/L, M (SD)

3.86 ± 1.46

4.66 ± 2.19

4.62 ± 2.25

6.50 ± 3.52

 < 0.001

WBC, 10^9/L, M (SD)

6.48 ± 1.83

7.30 ± 2.55

7.18 ± 2.52

8.77 ± 3.67

 < 0.001

Lymphocyte, 10^9/L, M (SD)

1.97 ± 0.73

1.92 ± 0.95

1.85 ± 0.65

1.49 ± 0.64

 < 0.001

RBC, 10^12/L, M (SD)

4.51 ± 0.58

4.43 ± 0.62

4.42 ± 0.65

4.23 ± 0.84

 < 0.001

Platelet, 10^9/L, M (SD)

218.79 ± 57.53

222.87 ± 70.99

222.73 ± 70.25

224.73 ± 81.19

0.295

TC, mmol/L, M (SD)

4.19 ± 1.43

4.29 ± 1.13

4.33 ± 1.11

4.24 ± 1.19

0.126

GFR, mL/min, M (SD)

78.93 ± 23.57

75.33 ± 23.71

72.90 ± 22.78

71.63 ± 21.75

 < 0.001

Blood glucose, mmol/L, M (SD)

5.97 ± 2.41

6.14 ± 2.50

5.91 ± 2.33

6.40 ± 3.10

0.002

NLR, MED (IQR)

1.93 (1.45,2.62)

2.35 (1.63, 3.33)

2.22 (1.73,3.18)

3.81 (2.61,6.72)

 < 0.001

Hs-CRP, mg/L, MED (IQR)

0.80 (0.44, 1.28)

4.61 (2.97, 8.42)

24.35 (15.06,24.35)

43.00 (24.35,88.05)

 < 0.001

  1. SBP systolic blood pressure, DBP diastolic blood pressure, BMI body mass index, LOS length of stay, EF ejection fraction, MI myocardial infarction, CVA cerebrovascular accident, PCI percutaneous coronary intervention, CABG coronary artery bypass graft surgery, DM diabetes mellitus, CKD chronic kidney disease, ACS acute coronary syndrome, AF atrial fibrillation, PAH pulmonary artery hypertension, HF heart failure, CCB Calcium Channel Blockers, ACEI or ARB or ARNI angiotensin-converting enzyme inhibitors or angiotensin receptor blockers or angiotensin receptor–neprilysin inhibitors, DAPT dual antiplatelet therapy, ALP albumin, Scr serum creatinine, NE neutrophils, WBC White blood cells, RBC red blood cells, TC total cholesterol, GFR glomeruar filtration rate, NLR neutrophil to lymphocyte ratio, Hs-CRP high-sensitivity C-reactive protein.
Back to article page